Trial Profile
A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Teprasiran (Primary)
- Indications Delayed graft function
- Focus Registrational; Therapeutic Use
- Acronyms ReGIFT
- Sponsors Quark Pharmaceuticals
- 18 Jul 2019 Status changed from active, no longer recruiting to completed.
- 05 Jun 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 15 Mar 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.